Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.60
- Piotroski Score 2.00
- Grade Buy
- Symbol (YMAB)
- Company Y-mAbs Therapeutics, Inc.
- Price $10.73
- Changes Percentage (-3.68%)
- Change -$0.41
- Day Low $10.54
- Day High $11.38
- Year High $20.90
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $21.50
- High Stock Price Target $24.00
- Low Stock Price Target $13.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.49
- Trailing P/E Ratio -24.45
- Forward P/E Ratio -24.45
- P/E Growth -24.45
- Net Income $-21,427,000
Income Statement
Quarterly
Annual
Latest News of YMAB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
The key criteria for dose selection in the GD2 SADA study were based on preclinical PK data, aiming for optimal dosing near the NOAEL. The CFO is confident in hitting Q4 revenue guidance of $87 to $95...
By Yahoo! Finance | 1 week ago -
While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate
Investing in stocks carries risks, but finding a high-quality company like Y-mAbs Therapeutics (YMAB) can yield significant returns. Despite recent fluctuations, its long-term performance and revenue ...
By Yahoo! Finance | 1 month ago -
Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners' Top Holdings Now?
Caligan Partners, a significant specialty hedge fund, focuses on healthcare investments in the US. They engage in activist strategies, pushing for strategic changes in companies to enhance shareholder...
By Yahoo! Finance | 3 months ago
